5300 MEMORIAL DRIVE, HOUSTON, TX
Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
Investor Presentation
Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
News, Securities Holder Rights or Indentures, Material Contracts
MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
Reg. FD
Announces Notice of Allowance for Japanese Patent Covering Annamycin
Shareholder votes
FY 2025
Q3
Q2
Q1
Amended Annual Report
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
PRER14A
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence